Waldenström Macroglobulinemia

Dr. Christine Chen – Princess Margaret Cancer Centre (Toronto, CA)

About Speaker

Dr. Christine Chen

Dr. Christine Chen – Princess Margaret Cancer Centre

Dr. Christine Chen is the Medical Director of the Autologous Stem Cell Transplant Program and Clinical Lead for the Immune Effector Cell (IEC) Therapy Program at the Princess Margaret Cancer Centre, University Health Network (UHN), in Toronto, Canada.  She is appointed as an Associate Professor at the University of Toronto (U of T) and is a member of the clinical research group for multiple myeloma and related mature B-cell disorders, including chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM).  Princess Margaret Cancer Centre is the largest tertiary care center for cancer in Canada, performing over 300 autologous stem cell transplants and seeing over 400 new referrals for myeloma, CLL and WM per year.  As Clinical Lead for the IEC Program, Dr. Chen led the implementation of CAR T-cell therapy at PM, one of only 6 centres in Canada certified to perform this complex, innovative therapy.  As a clinical investigator, Dr. Chen’s research interests are in the development of novel approaches for myeloma and CLL, focusing on cell-based therapy. Dr. Chen also holds the role of Quality Director for the Princess Margaret BMT-IEC Quality Program providing oversight for both standard of care and research cell therapy processes and maintaining FACT (Foundation for the Accreditation of Cellular Therapy) accreditation.

Thank you to our WHU 2021 Sponsors